Actinium, Astellas to create actinium-225 radiotherapies

By AuntMinnie.com staff writers

January 13, 2021 -- Immunotherapy technology developer Actinium Pharmaceuticals will work with Astellas Pharma to develop new actinium-225 targeted radiotherapies.

Actinium's antibody warhead-enabling platform and selected targeting agents from Astellas will be used to develop radiotherapies based on actinium-225, which has potential as a cancer-killing radioisotope.


Copyright © 2021 AuntMinnie.com
 
Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: